公司资料
Agenus 股价、新闻与催化剂
- 股票代码:
- AGEN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
7.67 USD (-5.19%)
收盘价
最后更新: 2026年8月24日
141M USD
市值
股价为何变动
As of Aug 24, 2026, AGEN closed down 5.19% at $7.67. No new same-company headline was identified in the current news window.
公司概览
业务概览
Agenus is an immuno-oncology company focused on cancer immunotherapy, including checkpoint and combination approaches. The company has spent years trying to turn immune science into a durable oncology franchise.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Agenus sits in specialty oncology biotechnology.
商业模式特征
The business depends on clinical data, strategic partnerships, and the ability to translate immunotherapy science into value.
生物医药行业定位
Agenus is a high-risk oncology name whose valuation is heavily dependent on clinical and strategic milestones.
未来催化剂
- Agenus's catalysts are botensilimab and balstilimab combination data, plus any partnering progression that can de-risk the program. The company still needs proof that the immuno-oncology story can keep moving.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。